Thromboprophylaxis in Pregnant Women with COVID-19: An Unsolved Issue

Varlas, Valentin Nicolae; Borş, Roxana Georgiana; Plotogea, Mihaela; Iordache, Madalina; Mehedințu, Claudia; Cîrstoiu, Monica Mihaela

doi:10.3390/ijerph20031949

Cited by 6 publications

(6 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since there aren't many research on pregnant women, this is challenging. [12,13] The cytokine storm caused by the SARS-CoV-2 is followed by a strong inflammatory response, as seen by the aberrant rise of D-dimers. Patients with COVID-19 have a higher mortality rate when their prothrombin time activity (PTact) is less than 75%, as well as increased D-dimers and fibrin degradation products.…”

Section: Discussionmentioning

confidence: 99%

The Impact of SARS-CoV-2 on the Coagulation Profile of Pregnant Women

Casap,

Ciobanu,

Moga

et al. 2024

BUT_Series_VI

View full text Add to dashboard Cite

A prospective study was conducted in the Clinic Hospital of Obstetrics and Gynecology "Dr. I.A. Sbârcea" Brașov, which included hospitalized pregnant women diagnosed with COVID-19 from January 1, 2020, to March 8, 2022. The study aimed to evaluate the influence of SARS-CoV-2 on the coagulation status, the blood levels of coagulation parameters, and the presence of disseminated intravascular coagulation in pregnant women with COVID-19. To analyze the coagulation status of the pregnant women we used the following parameters: Fibrinogen level, INR, D-dimer test, and the presence of disseminated intravascular coagulation. Following the study, we concluded that the occurrence of coagulation disorders in pregnant women is related to the severity of the SARS-CoV 2. LMWH administration generally improved the prognosis of pregnancy-associated COVID-19 and mostly prevented the occurrence of severe thromboembolic complications such as disseminated intravascular coagulation or deep venous thrombosis.

show abstract

Section: Discussionmentioning

confidence: 99%

The Impact of SARS-CoV-2 on the Coagulation Profile of Pregnant Women

Casap,

Ciobanu,

Moga

et al. 2024

BUT_Series_VI

View full text Add to dashboard Cite

show abstract

“…Lastly, the aim of this review was to record issues relating to antiviral and immunomodulating issues pertaining to COVID-19 pharmacotherapy. No information is reported regarding adjunctive or supporting care, e.g., anticoagulants [ 104 ], etc.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices

Akinosoglou

Schinas

Rigopoulos

et al. 2023

Viruses

View full text Add to dashboard Cite

The clinical management of COVID-19 in pregnant women, who are considered a vulnerable population, remains uncertain even as the pandemic subsides. SARS-CoV-2 affects pregnant individuals in multiple ways and has been associated with severe maternal morbidity and mortality, as well as neonatal complications. The unique anatomy and physiology of gestation make managing COVID-19 in this population a complex and challenging task, emphasizing the importance of spreading knowledge and expertise in this area. Therapeutic interventions require distinct clinical consideration, taking into account differences in pharmacokinetics, vertical transmission, drug toxicities, and postnatal care. Currently, there is limited data on antiviral and immunomodulating COVID-19 pharmacotherapy in pregnancy. Some medication has been shown to be safe and well tolerated among pregnant women with COVID-19; however, the lack of randomized clinical trials and studies in this patient population is evident. Available vaccines are considered safe and effective, with no evidence of harm to the fetus, embryo development, or short-term postnatal development. Pregnant women should be counseled about the risks of SARS-CoV-2 infection and informed of available ways to protect themselves and their families. Effective treatments for COVID-19 should not be withheld from pregnant individuals, and more research is needed to ensure the best outcomes.

show abstract

“…In contrast, other authors question thromboprophylaxis in pregnant women infected with SARS-CoV-2, especially for complications such as thrombophilia, preeclampsia, and intrauterine growth retardation [ 79 ].…”

Section: Pregnancy Thrombophilia and Covid-19mentioning

confidence: 99%

Endothelial Dysfunction and Pregnant COVID-19 Patients with Thrombophilia: A Narrative Review

Sekulovski,

Mileva,

Chervenkov

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Pregnancy with SARS-CoV-2 infection can raise the risk of many complications, including severe COVID-19 and maternal–fetal adverse outcomes. Additionally, endothelial damage occurs as a result of direct SARS-CoV-2 infection, as well as immune system, cardiovascular, and thrombo-inflammatory reactions. In this narrative review, we focus on endothelial dysfunction (ED) in pregnancy, associated with obstetric complications, such as preeclampsia, fetal growth retardation, gestational diabetes, etc., and SARS-CoV-2 infection in pregnant women that can cause ED itself and overlap with other pregnancy complications. We also discuss some shared mechanisms of SARS-CoV-2 pathophysiology and ED.

show abstract

Thromboprophylaxis in Pregnant Women with COVID-19: An Unsolved Issue

Cited by 6 publications

References 106 publications

The Impact of SARS-CoV-2 on the Coagulation Profile of Pregnant Women

The Impact of SARS-CoV-2 on the Coagulation Profile of Pregnant Women

COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices

Endothelial Dysfunction and Pregnant COVID-19 Patients with Thrombophilia: A Narrative Review

Contact Info

Product

Resources

About